Premium
Delayed Haematological recovery after autologous stem cell transplantation is associated with favourable outcome in acute myeloid leukaemia
Author(s) -
Wetzel Dana,
Mueller Beatrice U.,
Mansouri Taleghani Behrouz,
Baerlocher Gabriela M.,
Seipel Katja,
Leibundgut Kurt,
Pabst Thomas
Publication year - 2015
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13118
Subject(s) - medicine , npm1 , autologous stem cell transplantation , stem cell , transplantation , platelet , hematology , absolute neutrophil count , bone marrow , gastroenterology , myeloid , cd34 , oncology , immunology , chemotherapy , neutropenia , biology , karyotype , biochemistry , genetics , gene , chromosome
Summary Autologous stem cell transplantation ( ASCT ) is applied to consolidate first remission in patients with acute myeloid leukaemia ( AML ). However, outcome after ASCT widely varies among AML patients. We analyzed the prognostic significance of haematological recovery for neutrophils [absolute neutrophil count ( ANC ) >1·0 × 10 9 /l] and platelets (platelet count >20·0 × 10 9 /l), stratifying at day 20 after ASCT in 88 consecutive and homogeneously treated AML patients in first remission. We observed that patients with delayed recovery had better overall survival ( OS ; ANC : P < 0·0001 and platelets: P = 0·0062) and time to progression ( TTP ; ANC : P = 0·0003 and platelets: P = 0·0125). Delayed recovery was an independent marker for better OS and TTP in a multivariate analysis including age, gender, number of transfused CD 34+ cells, cytogenetics, FLT 3‐ internal tandem duplication and NPM 1 mutation. Our results suggest that delayed neutrophil and platelet recovery is associated with longer OS and TTP in AML patients consolidated with ASCT in first remission.